Clinical Trials Logo

Recurrent Glioblastoma clinical trials

View clinical trials related to Recurrent Glioblastoma.

Filter by:

NCT ID: NCT03216499 Recruiting - Clinical trials for Recurrent Glioblastoma

HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

PT2385
Start date: August 15, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03115333 Recruiting - Gliosarcoma Clinical Trials

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Start date: April 14, 2017
Phase: N/A
Study type: Interventional

This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient's response to treatment.

NCT ID: NCT03107780 Not yet recruiting - Glioblastoma Clinical Trials

MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma

Start date: October 27, 2017
Phase: Phase 1
Study type: Interventional

This phase 0/I trial studies the side effects and best dose of MDM2 inhibitor AMG-232 in treating patients with glioblastoma that is newly diagnosed or has come back. MDM2 inhibitor AMG-232 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03034135 Recruiting - Clinical trials for Recurrent Glioblastoma

Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Start date: March 9, 2017
Phase: Phase 2
Study type: Interventional

This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 weeks. Patients will be followed up 2 years after the last dose of DSF-Cu.

NCT ID: NCT03033524 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Study Design - Multicenter, open-label, 3 arms, stepwise, phase Ⅱa clinical trial Study objective: 1. Primary - To evaluate the safety of TTAC-0001 in patients with recurrent glioblastoma. 2. Secondary - To determine the efficacy of TTAC-0001 in patients with recurrent glioblastoma. 3. Exploratory - To evaluate pharmacokinetic (PK) parameters of TTAC-0001 in patients with recurrent glioblastoma - To evaluate pharmacodynamic (PD) parameters by clinical biomarker test Study Methodology Patients will be sequentially enrolled from the 1st arm. An enrollment criterion to the next arm is defined as no patients in the previous treatment arm showing grade ≥3 of hemangioma or other Dose Limiting Toxicities (DLT). A safety review committee (SRC) will convene to determine the patient's safety with a decision on enrollment into the next arm or change in dosing frequency of study drug in the above case. A patient who is withdrawn from the study before the completion of the 1st cycle can be replaced with another patient. Patients will be treated for up to 1 year, unless a cause for termination occurs, such as progression of disease (PD) or the withdrawal of consent.

NCT ID: NCT03020602 Recruiting - Gliosarcoma Clinical Trials

BPM31510 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Previously Treated With Bevacizumab

Start date: January 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ubidecarenone injectable nanosuspension (BPM31510) in treating patients with glioblastoma or gliosarcoma that has come back and have been previously treated with bevacizumab. BPM31510 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03020017 Recruiting - Gliosarcoma Clinical Trials

NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery

Start date: May 4, 2017
Phase: Early Phase 1
Study type: Interventional

The purpose of this research study is to evaluate the safety of the study drug, NU-0129, based on Spherical Nucleic Acid (SNA) platform when infused in patients with recurrent glioblastoma multiforme or gliosarcoma. The SNA consists of nucleic acids arranged on the surface of a small spherical gold nanoparticle. This is a first-in-human trial to determine the safety of NU-0129. NU-0129 can cross the blood brain barrier (a filtering mechanism that carry blood to the brain). Once within the tumor, the nucleic acid component is able to target a gene called Bcl2L12 that is present in glioblastoma multiforme, and is associated with tumor growth. This gene prevents tumor cells from apoptosis, which is the process of programmed cell death, thus promoting tumor growth. Researchers think that targeting the Bcl2L12 gene with NU-0129 will help stop cancer cells from growing.

NCT ID: NCT03014804 Not yet recruiting - Gliosarcoma Clinical Trials

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of autologous dendritic cells pulsed with tumor lysate antigen vaccine and nivolumab and to see how well they work in treating patients with glioblastoma that has come back. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving dendritic cell-autologous lung tumor vaccine and nivolumab may work better in treating patients with glioblastoma.

NCT ID: NCT02974621 Not yet recruiting - Clinical trials for Recurrent Glioblastoma

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Start date: September 15, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02844439 Recruiting - Glioblastoma Clinical Trials

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Start date: June 2016
Phase: Phase 2
Study type: Interventional

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.